Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer

Clinical trial NCT03348631 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT03348631
Sponsor: National Cancer Institute (NCI)
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Recurrent Endometrial Endometrioid Adenocarcinoma Recurrent Malignant Uterine Corpus Neoplasm Recurrent Ovarian Carcinoma Recurrent Ovarian Clear Cell Adenocarcinoma Recurrent Ovarian Endometrioid Adenocarcinoma

Start date: 2019-05-01
Primary completion: 2023-07-28
Enrollment: 62

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.